top of page


Kielo Research was founded to optimize the use of patient-centered science across the life sciences industry. We focus on patient preferences and their use in benefit-risk assessment as well as value communication.

“Patient centricity is now essential in drug and medical device development.”

Our Chief Scientist, Dr Tommi Tervonen, is a leading expert in the development and application of patient preference methods to inform drug and medical device development and market access. He has over 15 years of experience in patient preference elicitation, benefit-risk assessment, and multi-criteria decision analysis (MCDA).

His expertise influences decision maker opinion and he has been consulted by key agencies such as the US Food and Drug Administration (FDA) and UK National Institute of Health and Care Excellence (NICE). Dr Tervonen leads scientific initiatives such as the ISPOR Task Force on Good Practice in Quantitative Benefit-Risk Assessment and works with experts from FDA and European Medicines Agency (EMA) on advancing the use of patient preferences in regulatory decisions. His research appears frequently in leading clinical and methodological journals such as Thorax, Value in Health, and Medical Decision Making.


Dr Tervonen has served as principal investigator in dozens of patient preference studies across indications such as solid and haematological cancers, immune-related diseases including rheumatoid arthritis, multiple sclerosis, atopic dermatitis and alopecia areata, cardiovascular disease such as heart failure and myocardial infarction, neurological conditions such as migraine, and rare diseases. He was the principal investigator on the IMI PREFER industry case study on patient preferences for benefits and risks of blood thinners. Dr Tervonen led various studies included in successful regulatory filings to EMA and FDA, in HTA submissions, and in commercialization activities.



Kielo Research scientists are methodological leaders in their field. Our work has been published in leading methodological and clinical journals. By partnering with us, you ensure that your study will be publishable at top-tier journal.

Full list of publications is available at request here.

Selected publications

Angelis, A., R. Baltussen, and T. Tervonen. 2021. 'The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines', Am J Public Health, 111: 205-08.

Brooks, A., J. Langer, T. Tervonen, M. P. Hemmingsen, K. Eguchi, and E. D. Bacci. 2019. 'Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment', Diabetes Ther, 10: 735-49.

Collacott, H., D. Zhang, S. Heidenreich, and T. Tervonen. 2022. 'A Systematic and Critical Review of Discrete Choice Experiments in Asthma and Chronic Obstructive Pulmonary Disease', Patient, 15: 55-68.

Fox, R.J., Tervonen T., Phillips-Beyer, A., Sidorenko, T., Boyanova, N., Brooks, A. Hennessy, B., Jamieson C., Levitan, B. 2022. ‘The relevance of fatigue to relapse rate in multiple sclerosis: applying patient preference data to the OPTIMUM trial’, Mult Scler J.

He, J., A. Duenas, H. Collacott, A. Lam, K. S. Gries, R. Carson, D. Potthoff, N. Trevor, and T. Tervonen. 2021. 'Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany', Patient, 14: 613-23.

Mauer, J., K. Bullok, S. Watt, E. Whalen, L. Russo, R. Junor, J. Markman, B. Hauber, and T. Tervonen. 2022. 'Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis', Br J Clin Pharmacol, 88: 3837-46.

Mott, D. J., N. Chami, and T. Tervonen. 2020. 'Reporting Quality of Marginal Rates of Substitution in Discrete Choice Experiments That Elicit Patient Preferences', Value Health, 23: 979-84.

Pinto, C. A., G. N. Chua, J. F. P. Bridges, E. Brookes, J. Hyacinthe, and T. Tervonen. 2022. 'Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment', Patient, 15: 255-66.


Seo, J., C. A. Smith, C. Thomas, T. Tervonen, A. Hareendran, J. H. Ford, V. L. Stauffer, R. A. Nicholson, K. H. Duffy, and A. Tockhorn-Heidenreich. 2022. 'Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study', Patient, 15: 93-108.


Tervonen, T., A. Angelis, K. Hockley, F. Pignatti, and L. D. Phillips. 2019. 'Quantifying Preferences in Drug Benefit-Risk Decisions', Clin Pharmacol Ther, 106: 955-59.


Tervonen, T., H. Gelhorn, S. Sri Bhashyam, J. L. Poon, K. S. Gries, A. Rentz, and K. Marsh. 2017. 'MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment', Pharmacoepidemiol Drug Saf, 26: 1483-91.


Tervonen, T., N. Hawken, N. A. Hanania, F. J. Martinez, S. Heidenreich, and I. Gilbert. 2020. 'Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment', Thorax, 75: 735-43.


Tervonen, T., A. C. Jimenez-Moreno, N. Krucien, H. Gelhorn, K. Marsh, and S. Heidenreich. 2021. 'Willingness to Wait for a Vaccine Against COVID-19: Results of a Preference Survey', Patient, 14: 373-77.


Tervonen, T., F. J. Martinez, N. A. Hanania, S. Heidenreich, J. M. Eudicone, and I. Gilbert. 2021. 'Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment', Respir Med, 176: 106278.


Tervonen, T., F. Pignatti, and D. Postmus. 2019. 'From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs', Med Decis Making, 39: 879-85.


Tervonen, T., T. Prawitz, G. N. Chua, J. Hyacinthe, and C. A. Pinto. 2022. 'Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment', J Clin Epidemiol, 144: 84-92.


Tervonen, T., T. Schmidt-Ott, K. Marsh, J. F. P. Bridges, M. Quaife, and E. Janssen. 2018. 'Assessing Rationality in Discrete Choice Experiments in Health: An Investigation into the Use of Dominance Tests', Value Health, 21: 1192-97.

Tervonen, T., P. Vora, J. Seo, N. Krucien, K. Marsh, R. De Caterina, U. Wissinger, and M. Soriano Gabarro. 2021. 'Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis', Patient, 14: 661-72.

Thomas, C., A. Raibouaa, A. Wollenberg, J. P. Capron, N. Krucien, H. Karn, and T. Tervonen. 2022. 'Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment', BMJ Open, 12: e058799.

bottom of page